Conatus Pharmaceuticals, Inc. (NASDAQ: CNAT) Starts Presentation at 29th Annual ROTH Conference
Conatus Pharmaceuticals (NASDAQ: CNAT) is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. The company is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease. For more information, visit the company’s website www.conatuspharma.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a…







